Summary of Human Pharmacodynamic and Cardiac-Safety (QT) Study Reports — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The human PD (biomarker) evidence and the ICH E14 cardiac-safety (thorough-QT / concentration–QTc) assessment.
Why it exists. Regulators require proof a drug does not dangerously prolong the heart's QT interval. This report shows the double-negative conclusion (negative nonclinical hERG plus a clinical upper 90% CI under 10 ms) alongside the target-engagement biomarkers that distinguish the dual agonist.
How it is produced here. It is a clinical-pharmacology study report. Because this portfolio simulates only the Phase 3 clinical dataset, the PK/PD, immunogenicity, and assay values here are deep-knowledge mock — realistic, standard-conformant numbers that stand in for the individual clin-pharm study reports, kept consistent with the trial's pharmacology and the Investigator's Brochure.
Format & governing standard. —
Summary of Human Pharmacodynamic and Cardiac-Safety (QT) Study Reports — GLPI-103
| Field | Value |
|---|---|
| Document ID | CLINPHARM-003 |
| Version | 1.0 |
| Status | Final |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| CTD location | Module 5.3.4 — Reports of Human Pharmacodynamic (PD) Studies |
| Standard(s) | ICH E14 (clinical QT) & E14/S7B Q&A (concentration–QTc); ICH E16 (biomarkers) |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]No dedicated PD/QT dataset is simulated. Findings are illustrative and consistent with the nonclinical safety-pharmacology package (M4-2.1, negative hERG/telemetry), IB-001, and REF-002. This document stands in for the individual PD and thorough-QT study reports a real submission would file.
Change History
| Version | Date | Author | Summary of Change |
|---|---|---|---|
| 1.0 | 2026-07-05 | Clinical Pharmacology | Initial submission-grade summary of human PD (biomarker) and cardiac-safety (QT) evidence |
Abbreviations
C–QTc concentration–QTc analysis · ΔΔQTcF placebo-corrected change-from-baseline QTcF · ECG electrocardiogram · HR heart rate · QTcF Fridericia-corrected QT interval · TQT thorough QT study.
1. Pharmacodynamic Biomarkers [MOCK]
GLPI-103 engages two receptor systems; the PD program characterized both target engagement and the downstream metabolic and cardiometabolic effects.
| Biomarker | Rationale (pathway) | Observed direction (dose-dependent) |
|---|---|---|
| Plasma apelin | APJ-pathway target engagement | Modulated, confirming APJ engagement |
| Fasting/postprandial glucose, HbA1c | GLP-1 insulinotropic/glucagonostatic | Reduced (efficacy readout; Phase 2/3) |
| Body weight, food intake | GLP-1 appetite/gastric emptying | Reduced |
| NT-proBNP, hsCRP, IL-6 | APJ cardiometabolic / anti-inflammatory | Favourable change [MOCK — not captured in Phase-3 dataset] |
| HOMA-IR, adiponectin | insulin sensitivity | Improved |
Target engagement was evident from the first-in-human studies (plasma apelin, glucose) and a clear dose–response for glycaemic and weight effects was established in Phase 2 (CSR-201), supporting the Phase 3 dose selection. The mechanistic cardiometabolic biomarkers (NT-proBNP, hsCRP) differentiate the dual agonist from GLP-1-only agents but were pre-specified rather than captured in the simulated Phase 3 dataset (CSR-301 §11.5).
2. Cardiac Safety — Effect on the QT/QTc Interval [MOCK]
Cardiac repolarization risk was evaluated under ICH E14 using a concentration–QTc (C–QTc) approach supported by the nonclinical package.
2.1 Nonclinical anchor
In vitro hERG assays and in vivo cardiovascular telemetry (M4-2.1, safety pharmacology, ICH S7A/S7B) demonstrated no QT/hERG liability, with only transient, mechanism-related heart-rate changes typical of incretin agonists. This provided the nonclinical basis for the clinical strategy.
2.2 Clinical QT evaluation
A dedicated evaluation combining intensive ECG collection at supratherapeutic exposure with a concentration–QTc analysis (E14/S7B Q&A double-negative approach) was performed.
| Endpoint | Result | Threshold of regulatory concern |
|---|---|---|
| Upper bound of 90% CI for ΔΔQTcF at Cmax | < 10 ms at therapeutic and supratherapeutic exposure | 10 ms |
| C–QTc slope | shallow, not significantly positive | — |
| Assay sensitivity (moxifloxacin positive control) | demonstrated | required for validity |
| Categorical outliers (QTcF > 500 ms; ΔQTcF > 60 ms) | none of concern | — |
Heart rate: a modest increase in heart rate was observed, consistent with the incretin/APJ class and with the nonclinical telemetry; this was not accompanied by a repolarization signal.
2.3 Conclusion on QT
GLPI-103 does not prolong the QTcF interval to a clinically relevant degree (upper bound of the 90% CI < 10 ms). The clinical finding is concordant with the negative nonclinical hERG/telemetry data, supporting a "double-negative" cardiac-safety conclusion under the E14/S7B Q&A. A modest, expected heart-rate increase is described in the labeling. These conclusions are integrated in Module 2.7.2 (Clinical Pharmacology) and the Clinical Safety Summary (M2.7.4); Phase-3 vital-sign data showed no clinically meaningful heart-rate change (CSR-301 §12.6).
3. References
IB-001 §4.1, §5.2; M4-2.1 (safety pharmacology); M2.7.2 (clinical pharmacology); M2.7.4 (clinical safety); CSR-201; CSR-301; REF-002; ICH E14 & E14/S7B Q&A.
Comments (0)
No comments yet. Be the first to say something!